BMS-564,929 (original) (raw)
BMS-564,929 is an investigational selective androgen receptor modulator (SARM) which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). These symptoms may include depression, loss of muscle mass and strength, reduction in libido and osteoporosis. Treatment with exogenous testosterone is effective in counteracting these symptoms but is associated with a range of side effects, the most serious of which is enlargement of the prostate gland, which can lead to benign prostatic hypertrophy and even prostate cancer. This means there is a clinical need for selective androgen receptor modulators, which produce anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in
| Property | Value |
|---|---|
| dbo:abstract | BMS-564,929 is an investigational selective androgen receptor modulator (SARM) which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). These symptoms may include depression, loss of muscle mass and strength, reduction in libido and osteoporosis. Treatment with exogenous testosterone is effective in counteracting these symptoms but is associated with a range of side effects, the most serious of which is enlargement of the prostate gland, which can lead to benign prostatic hypertrophy and even prostate cancer. This means there is a clinical need for selective androgen receptor modulators, which produce anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in the prostate. BMS-564,929 is one such compound currently in early human clinical trials, which is an orally active, potent and selective agonist for androgen receptors (Ki 2.1nM, 20x functional selectivity for muscle tissue over prostate) and in studies on castrated rats it was shown to counteract decrease in muscle mass over time, and at higher doses even increased muscle mass, without significantly affecting prostate tissue. It does however vastly reduce luteinizing hormone levels, it being an astonishing 33× more suppressive compound than testosterone, which may be a problem in human clinical use. Selective androgen receptor modulators may also be used by athletes to assist in training and increase physical stamina and fitness, potentially producing effects similar to anabolic steroids but with significantly fewer side effects. For this reason, SARMs have already been banned by the World Anti-Doping Agency since January 2008 despite no drugs from this class yet being in clinical use, and blood tests for all known SARMs are currently being developed. (en) |
| dbo:casNumber | 627530-84-1 |
| dbo:chEMBL | 229264 |
| dbo:drugbank | DB07286 |
| dbo:fdaUniiCode | 9BLW27W4X7 |
| dbo:pubchem | 9882972 |
| dbo:thumbnail | wiki-commons:Special:FilePath/BMS-564,929.svg?width=300 |
| dbo:wikiPageExternalLink | http://www.rcsb.org/pdb/explore/explore.do%3FpdbId=2NW4 |
| dbo:wikiPageID | 19943267 (xsd:integer) |
| dbo:wikiPageLength | 6341 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1092789368 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Prostate_gland dbr:Muscle dbr:Andropause dbr:Depression_(mood) dbr:Libido dbc:Chlorobenzenes dbc:Lactams dbc:Secondary_alcohols dbc:Ureas dbr:Functional_selectivity dbr:Prostate_cancer dbr:Protein_Data_Bank dbr:Bristol-Myers_Squibb dbr:Physical_strength dbc:Imides dbr:Dissociation_constant dbr:Anabolic dbr:Anabolic_steroid dbr:Osteoporosis dbc:Nitriles dbr:Testosterone_(medication) dbc:Selective_androgen_receptor_modulators dbc:Bristol_Myers_Squibb dbc:Pyrroloimidazoles dbr:Selective_androgen_receptor_modulator dbr:World_Anti-Doping_Agency dbr:Luteinizing_hormone dbr:Benign_prostatic_hypertrophy |
| dbp:c | 14 (xsd:integer) |
| dbp:casNumber | 627530 (xsd:integer) |
| dbp:chembl | 229264 (xsd:integer) |
| dbp:chemspiderid | 8058647 (xsd:integer) |
| dbp:cl | 1 (xsd:integer) |
| dbp:drugbank | DB07286 (en) |
| dbp:h | 12 (xsd:integer) |
| dbp:iupacName | 4 (xsd:integer) |
| dbp:legalUs | Investigational New Drug (en) |
| dbp:n | 3 (xsd:integer) |
| dbp:o | 3 (xsd:integer) |
| dbp:pubchem | 9882972 (xsd:integer) |
| dbp:smiles | CC1=CN2C[C@@H]3[C@@H]O (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | KEJORAMIZFOODM-PWSUYJOCSA-N (en) |
| dbp:unii | 9 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 424678818 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Androgen_receptor_modulators dbt:Drugbox dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite |
| dcterms:subject | dbc:Chlorobenzenes dbc:Lactams dbc:Secondary_alcohols dbc:Ureas dbc:Imides dbc:Nitriles dbc:Selective_androgen_receptor_modulators dbc:Bristol_Myers_Squibb dbc:Pyrroloimidazoles |
| gold:hypernym | dbr:Modulator |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatUreas yago:WikicatNitriles yago:Abstraction100002137 yago:Agent114778436 yago:Alcohol107884567 yago:Beverage107881800 yago:CausalAgent100007347 yago:Chemical114806838 yago:Compound114818238 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:Fluid114939900 yago:Food100021265 yago:Imide115110666 yago:Liquid114940386 yago:Material114580897 yago:Matter100020827 yago:Nitrile114827346 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Relation100031921 yago:WikicatImides dbo:Drug yago:Substance100019613 yago:Substance100020090 yago:Urea115085472 yago:WikicatAlcohols umbel-rc:DrugProduct |
| rdfs:comment | BMS-564,929 is an investigational selective androgen receptor modulator (SARM) which is being developed by Bristol-Myers Squibb for treatment of the symptoms of age-related decline in androgen levels in men ("andropause"). These symptoms may include depression, loss of muscle mass and strength, reduction in libido and osteoporosis. Treatment with exogenous testosterone is effective in counteracting these symptoms but is associated with a range of side effects, the most serious of which is enlargement of the prostate gland, which can lead to benign prostatic hypertrophy and even prostate cancer. This means there is a clinical need for selective androgen receptor modulators, which produce anabolic effects in some tissues such as muscle and bone, but without stimulating androgen receptors in (en) |
| rdfs:label | BMS-564,929 (en) |
| owl:sameAs | freebase:BMS-564,929 yago-res:BMS-564,929 wikidata:BMS-564,929 dbpedia-sh:BMS-564,929 dbpedia-sr:BMS-564,929 https://global.dbpedia.org/id/4UpSk |
| prov:wasDerivedFrom | wikipedia-en:BMS-564,929?oldid=1092789368&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/BMS-564,929.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:BMS-564,929 |
| is dbo:wikiPageRedirects of | dbr:C14H12ClN3O3 dbr:BMS-564929 |
| is dbo:wikiPageWikiLink of | dbr:List_of_designer_drugs dbr:C14H12ClN3O3 dbr:Nonsteroidal dbr:RAD140 dbr:Selective_androgen_receptor_modulator dbr:BMS-564929 |
| is foaf:primaryTopic of | wikipedia-en:BMS-564,929 |
